期刊文献+

藤黄酸长循环脂质体制备及药动学研究 被引量:8

Preparation and pharmacokinetics of gambogic acid long-circulating liposomes
原文传递
导出
摘要 目的优化藤黄酸长循环脂质体制备工艺,并对其体外释放及体内药动学进行研究。方法建立藤黄酸定量测定方法;以藤黄酸包封率作为考察指标,采用Box-Behnken试验设计优化脂质体组方,得到藤黄酸包封率最高的处方;采用电镜扫描观察藤黄酸脂质体表面形态,采用透析法对脂质体体外释放进行研究,测定藤黄酸在15 d内的稳定性;雄性Wistar大鼠尾静脉分别注射1 mg/m L藤黄酸、藤黄酸脂质体后,采用UPLC-MS/MS方法测定血药浓度,比较2种药物药动学参数差异。结果 Box-Behnken优化后脂质体最优处方为胆固醇444 mg、蛋黄磷脂酰胆碱1 823 mg和二硬脂酰基磷脂酰乙醇胺-聚乙二醇705 mg,脂质体包封达到92.3%,脂质体粒径均一,表面光滑;体外释放结果表明脂质体可以平缓释放,且具有长效作用,在15 d内储存稳定;脂质体中藤黄酸的体内半衰期为9.97 h,是藤黄酸的4.43倍;脂质体中藤黄酸的AUC0~24 h为22.55μg·h/m L,是藤黄酸的4.73倍。结论藤黄酸脂质体与原料药相比具有长循环、血药浓度高、释放平缓等特点。 Objective To optimize the preparation process of gambogic acid(GA) liposomes and study the in vitro and in vivo release. Methods The detection method of GA was established, using the Box-Behnken experiment design to optimize liposomes formula, GA liposomes were obtained with the highest encapsulation efficiency; Using scanning electron micrographs(SEM) to observe liposome surface morphology, using the dialysis method to study the liposome release in vitro, we also measured the stability of liposome in 15 d; Male Wistar rats were injected with GA or GA liposomes(1 mg/m L) via tail vein, UPLC-MS/MS method was used to determine the drug concentration, and differences in pharmacokinetic parameters of the two drugs were compared. Results After Box-Behnken optimization, the encapsulation efficiency of liposomes was 92.3%, and the optimized liposomes formula is cholesterol of 440 mg, egg phosphatidylcholine of 1823 mg,,and istearoyl phosphoethanolamine-PEG 2000 of 705 mg, liposomes had uniform particle size and smooth surface; In vitro release results showed that the liposomes could be gentle and slowly release and had a longterm effect. The liposomes were stable keeping in 4 ℃ within 15 d; In in vivo study, the half-life of GA liposome was 9.97 h, 4.43 times of GA; AUC0—24 h of GA liposome was 22.55 μg·h/m L, 4.73 times of GA. Conclusion Compared with GA, GA liposome has the characteristics of long-circulating, high blood drug concentration, and could release smoothly.
出处 《中草药》 CAS CSCD 北大核心 2016年第8期1309-1314,共6页 Chinese Traditional and Herbal Drugs
关键词 藤黄酸 长循环脂质体 中心组合 药动学 BOX-BEHNKEN试验设计 体外释放 UPLC-MS/MS gambogic acid long-circulating liposome central composite design pharmacokinetics Box-Behnken test design in vitro release UPLC-MS/MS
  • 相关文献

参考文献18

  • 1杨企铮,贾淑杰,李德华.中药藤黄的近代研究[J].中国肿瘤临床,1994,21(6):464-466. 被引量:18
  • 2Park M S, Kim N H, Kang C W, et al. Antimetastatic effects of gambogic acid are mediated via the actin cytoskeleton and NF-κB pathways in SK-HEP 1 cells [J]. Drug Develop Res, 2015, 76(3): 132-142.
  • 3Wang S P, Wang L, Chen M W, et al. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression [J]. Chem-Biol Interact, 2015, 235: 76-84.
  • 4Lu N, Hui H, Yang H, et al. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway [J]. EurJPharm Sci, 2013, 49(2): 220-226.
  • 5Yin D K, Yang Y, Cai H X, et al. Gambogic acid-loaded electrosprayed particles for site-specific treatment of hepatocellular carcinoma [J]. Mol Pharm, 20!4, 11(11): 4107-4117.
  • 6侯文洁,陈保来,赵祎武,萧伟.藤黄酸稳定性研究[J].中草药,2011,42(9):1755-1758. 被引量:7
  • 7郝琨,柳晓泉,王广基.藤黄酸在大鼠体内的药代动力学[J].中国药科大学学报,2005,36(4):338-341. 被引量:18
  • 8Yao J, Li Y K, Sun X J, et al. Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid [J]. lntJNanomed, 2014, 9(1): 3313-3324.
  • 9张文君,吴凡,王鑫,谭亚楠,李艺,陈立江.星点设计-效应面法优化藤黄酸纳米混悬剂处方[J].中国药剂学杂志(网络版),2014,12(2):43-52. 被引量:5
  • 10王盈.用于口服给药的藤黄酸-乳铁蛋白纳米粒[J].中国医药工业杂志,2013,44(4):332-332. 被引量:1

二级参考文献69

共引文献68

同被引文献59

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部